David Clemmons, MD
David Clemmons, MD is the Sarah Graham Kenan Professor of Medicine at the University of North Carolina School of Medicine at Chapel Hill.
Dr. Clemmons’s goal is to develop a synthetic peptide drug as a drug for the treatment of osteoporosis. Severe osteoporosis is an extensive clinical problem (four million fractures/year) that to increased morbidity and mortality. Currently only one approved drug stimulates bone formation and it has significant limitations.
The studies that Dr. Clemmons is conducting with the Harrington Discovery Institute are based on a novel mechanism by which IGFBP-2 stimulates bone formation. The cell surface receptor RPTPβ that mediates these effects has been identified and its signaling pathway determined. Activation of this pathway enhances bone formation.
The novel discovery is a 13 amino acid peptide contains the site in the ligand that binds to the receptor and that it replicates the effects of the intact protein. The approach is innovative and does not utilize currently available approaches for treating osteoporosis.
Dr. Clemmons earned his MD at the University of North Carolina School of Medicine at Chapel Hill. He completed his internship in medicine at Massachusetts General Hospital in Boston, and his residencies at Massachusetts General Hospital and Johns Hopkins Hospital in Baltimore, Maryland.